The technologies presented for the ultrahigh sensitivity of cTnI assay can also potentially open up an opportunity of removing the need that patients with emergent cardiovascular diseases, such as acute coronary syndromes, should wait several hours until their level in blood rises to the level detectable by the assay devices and kits currently available in the emergency medical center. The gene discussed is TNNI3; the disease is acute coronary syndrome.